TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The FDA said Oct. 20, 2026, that it had approved Zydus Pharmaceuticals’ generic version of Climara Pro, a combination hormone therapy patch applied once a week. It is indicated for moderate to severe menopausal vasomotor symptoms and prevention of postmenopausal osteoporosis in women with an intact uterus; price and availability were not provided.
The U.S. Food and Drug Administration has approved Zydus Pharmaceuticals’ generic estradiol and levonorgestrel patch, a once-weekly hormone therapy for women with an intact uterus. Announced Oct. 20, the approval makes the first generic version of Climara Pro available as an FDA-approved option for treating moderate to severe menopausal hot flashes and related vasomotor symptoms, and for preventing postmenopausal osteoporosis.
The product is a transdermal patch containing estradiol and levonorgestrel, with strengths listed by the FDA as 0.045 milligrams per day and 0.015 milligrams, respectively. It is applied once a week. The agency says the generic is therapeutically equivalent to Climara Pro, the branded medicine, and is approved for the same uses in women with an intact uterus.
Unlike estrogen-only patches, this product combines estrogen and a progestogen in one patch. The FDA says the progestogen is included to reduce the risk of endometrial hyperplasia, an abnormal thickening of the uterine lining that can occur with estrogen use alone. The agency’s approval does not mean the patch is appropriate for every person experiencing menopause; the indication and safety information are specific to the product and patient population.
The FDA lists application-site reactions, vaginal bleeding, breast pain, upper respiratory infection, back pain, depression, pain, headache and flu syndrome among the most common adverse reactions, each reported at a rate of at least 5% in the product’s prescribing information. The agency also lists conditions that make use of the medicine contraindicated, including certain current or past blood clots, breast cancer or a history of it, unexplained abnormal genital bleeding, liver disease and specified blood-clotting disorders. Patients should review the full prescribing information with a health professional.
A Generic Option for Weekly Therapy
The approval adds a generic alternative to a branded combination patch for patients and clinicians considering hormone therapy for the product’s approved uses. Generic medicines can introduce additional competition, which may affect treatment costs and access. The FDA says nine out of 10 prescriptions filled in the United States are for generic drugs, and it describes greater generic availability as a way to support competition and affordability.
However, the announcement provides no price, launch date or availability details for Zydus’s product. FDA approval establishes that the medicine met the agency’s approval requirements; it does not establish what patients will pay or whether the product is already stocked by pharmacies. The manufacturer is the source for current availability information.
The weekly schedule may also be relevant for people who prefer a patch to a daily oral medicine. FDA Center for Drug Evaluation and Research Director Michael Davis said once-weekly dosing can affect how patients manage care and described a patch as a convenient alternative to daily oral medication. That is an agency official’s general view, not evidence in this announcement that the generic will improve adherence for every patient.
As an affiliate, we earn on qualifying purchases.
How the Combination Patch Is Used
Climara Pro is a registered trademark of Bayer. The FDA’s announcement identifies the approved generic as Estradiol and Levonorgestrel Transdermal System and names Zydus Pharmaceuticals (USA) Inc. as its manufacturer. The agency characterized the product as the first generic of Climara Pro.
The product is not interchangeable in purpose with every menopause treatment: its FDA-listed uses are moderate to severe vasomotor symptoms due to menopause and prevention of postmenopausal osteoporosis, for women with an intact uterus. The two-hormone formulation is distinct from estrogen-only patches because it includes levonorgestrel, a progestogen. The FDA says that component is included to reduce the risk of endometrial hyperplasia associated with estrogen alone.
The FDA placed the approval under its Public Health Pillar on increasing access to affordable medicines and medical products. Its release also points readers to the agency’s resources on generic drugs and the Orange Book, which lists approved drug products and therapeutic equivalence evaluations. These references provide regulatory context; they do not disclose the generic patch’s retail cost or supply.
“Menopause is a universal experience for women, and it can greatly affect a person’s quality of life. This approval makes effective treatment more accessible.”
— Acting FDA Commissioner Kyle Diamantas
estradiol levonorgestrel transdermal patch
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Price and Pharmacy Availability
The FDA release does not say when Zydus’s generic will reach pharmacies, what it will cost, or how its price will compare with Climara Pro. It directs consumers to contact the manufacturer for availability information. The announcement also does not give details about insurance coverage, supply levels or whether the product will be offered through particular pharmacies.
The approval announcement is not a substitute for individualized medical advice. Whether this therapy is suitable depends on a patient’s health history and the medicine’s labeled uses and risks. The release lists multiple contraindications and adverse reactions, but does not provide patient-specific guidance or discuss how an individual’s risks should be weighed against potential benefits.
weekly hormone therapy patch for women
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Manufacturer to Confirm Market Launch
Zydus Pharmaceuticals is the source identified by the FDA for current availability information. Patients and clinicians will need to check with the manufacturer, pharmacies or insurers for launch timing, supply and out-of-pocket cost. The FDA’s Orange Book is another agency resource for the approved product and therapeutic-equivalence information.
In the meantime, people considering the patch should consult a qualified health professional and review the full prescribing information, including contraindications and adverse reactions. The FDA announcement confirms regulatory approval, but leaves commercial availability and pricing unresolved.
As an affiliate, we earn on qualifying purchases.
Key Questions
What did the FDA approve?
The FDA approved Zydus Pharmaceuticals’ generic estradiol and levonorgestrel transdermal system, a once-weekly patch and the first generic version of Climara Pro, according to the agency.
Who is the patch approved for?
The FDA lists its uses for women with an intact uterus: treatment of moderate to severe vasomotor symptoms due to menopause and prevention of postmenopausal osteoporosis. A health professional can advise whether it is appropriate for a particular patient.
How is this patch different from an estrogen-only patch?
It contains both estradiol, an estrogen, and levonorgestrel, a progestogen. The FDA says the progestogen is included to reduce the risk of endometrial hyperplasia that can occur with estrogen use alone.
When will the generic be available, and how much will it cost?
The FDA’s announcement does not provide a launch date or price. It advises consumers to contact the manufacturer for availability information; pharmacy and insurance costs may also need to be checked directly.
What safety information did the FDA highlight?
The FDA lists several contraindications, including certain current or past blood clots, breast cancer or a history of it, unexplained abnormal genital bleeding and liver disease. Common adverse reactions include application-site reactions, vaginal bleeding, breast pain and headache. Patients should consult a health professional and review the full prescribing information.
Source: primary
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
